{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:44:01Z","timestamp":1780994641659,"version":"3.54.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"name":"Ningbo Top Medical and Health Research Program","award":["2023010211"],"award-info":[{"award-number":["2023010211"]}]},{"name":"Zhejiang Provincial Medicine and Health Research Foundation","award":["2023KY040"],"award-info":[{"award-number":["2023KY040"]}]},{"name":"Zhejiang Provincial Medicine and Health Research Foundation","award":["2024KY1584"],"award-info":[{"award-number":["2024KY1584"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    Inflammatory myofibroblastic tumors (IMTs) of the urinary bladder are rare mesenchymal neoplasms with an incompletely defined molecular spectrum. This integrated clinicopathologic and molecular study of 20 bladder IMTs utilized immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and targeted RNA sequencing to characterize their molecular drivers. Clinically, patients (mean age 45\u00a0y) presented with hematuria (85%) and cystoscopic polypoid\/nodular masses; despite muscularis propria invovlement (55%) or perivesical soft tissue extension (5%), clinical outcomes were excellent (90% disease-free survival; mean follow-up 32.6\u00a0mo), with 2 recurrences managed by repeat resection. Histologically, the tumors exhibited mixed growth patterns: compact spindle cell (75%), myxoid (50%), and hypocellular fibrous (20%), with 45% showing combined features. IHC revealed ALK positivity in 90% (18\/20) of cases, predominantly diffuse cytoplasmic staining (17\/18), while keratins (AE1\/AE3 and\/or CAM5.2) were positive in 83.3%. Molecular analysis identified\n                    <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                    rearrangements in 87.5% (14\/16) of FISH-tested cases (signal separation: 13% to 42%) and gene fusions in 88.9% (16\/18) of RNA-sequenced cases, with\n                    <jats:italic toggle=\"yes\">FN1::ALK<\/jats:italic>\n                    being the predominant fusion (75%, 12\/16). Rare fusions included\n                    <jats:italic toggle=\"yes\">VCL::ALK<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">DCTN1::ALK<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">PPFIBP1::ALK<\/jats:italic>\n                    , and a novel\n                    <jats:italic toggle=\"yes\">TFG::ROS1<\/jats:italic>\n                    (confirmed by RT-PCR and Sanger sequencing). Distinct genotype-phenotype correlations emerged: myxoid morphology strongly associated with\n                    <jats:italic toggle=\"yes\">FN1::ALK<\/jats:italic>\n                    (87.5%, 7\/8), while hypocellular fibrous patterns enriched non-\n                    <jats:italic toggle=\"yes\">FN1<\/jats:italic>\n                    fusions (75%, 3\/4). The predominance of\n                    <jats:italic toggle=\"yes\">FN1::ALK<\/jats:italic>\n                    fusions, sharing identical breakpoints (\n                    <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                    exons 18 to 19) with pseudosarcomatous myofibroblastic proliferations of the urinary bladder, alongside expanded molecular diversity (non-\n                    <jats:italic toggle=\"yes\">FN1\/ROS1<\/jats:italic>\n                    fusions), supports their classification as a biological continuum of\n                    <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                    -driven bladder mesenchymal neoplasms. These findings broaden the molecular genetic spectrum of bladder IMTs and advocate for histology-guided molecular testing to identify kinase fusions, reinforcing conservative management for these typically indolent tumors.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002477","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T06:00:10Z","timestamp":1760594410000},"page":"118-131","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Heterogeneity and Clinicopathologic Correlations in Inflammatory Myofibroblastic Tumors of the Urinary Bladder"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5971-7303","authenticated-orcid":false,"given":"Ming","family":"Zhao","sequence":"first","affiliation":[{"name":"Ningbo Clinical Pathology Diagnosis Center, Ningbo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ruijin Hospital of Shanghai Jiaotong University, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Ningbo Clinical Pathology Diagnosis Center, Ningbo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fang","sequence":"additional","affiliation":[{"name":"Ningbo Clinical Pathology Diagnosis Center, Ningbo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayun","family":"Xu","sequence":"additional","affiliation":[{"name":"Ningbo Clinical Pathology Diagnosis Center, Ningbo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Ningbo Clinical Pathology Diagnosis Center, Ningbo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[{"name":"Ningbo Clinical Pathology Diagnosis Center, Ningbo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cancer Center, Zhejiang Province People\u2019s Hospital, People\u2019s Hospital of Hangzhou Medical College, Hangzhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suying","family":"Wang","sequence":"additional","affiliation":[{"name":"Ningbo Clinical Pathology Diagnosis Center, Ningbo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"R2-20251215","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/00000478-199508000-00001","article-title":"Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases","volume":"19","author":"Coffin","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"R3-20251215","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/01.pas.0000213393.57322.c7","article-title":"Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases","volume":"31","author":"Coffin","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R4-20251215","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jcp.2007.049387","article-title":"Inflammatory myofibroblastic tumours: where are we now?","volume":"61","author":"Gleason","year":"2008","journal-title":"J Clin Pathol"},{"key":"R5-20251215","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0002-9440(10)64550-6","article-title":"TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors","volume":"157","author":"Lawrence","year":"2000","journal-title":"Am J Pathol"},{"key":"R6-20251215","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9440(10)61711-7","article-title":"Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor","volume":"159","author":"Bridge","year":"2001","journal-title":"Am J Pathol"},{"key":"R7-20251215","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/01.LAB.0000088856.49388.EA","article-title":"Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor","volume":"83","author":"Debelenko","year":"2003","journal-title":"Lab Invest"},{"key":"R8-20251215","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/gcc.10267","article-title":"ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor","volume":"38","author":"Debiec-Rychter","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"R9-20251215","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/gcc.10177","article-title":"Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor","volume":"37","author":"Ma","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"R10-20251215","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/path.4836","article-title":"ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma","volume":"241","author":"Lee","year":"2017","journal-title":"J Pathol"},{"key":"R11-20251215","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/2159-8290.CD-14-0377","article-title":"Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions","volume":"4","author":"Lovly","year":"2014","journal-title":"Cancer Discov"},{"key":"R12-20251215","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/PAS.0000000000000404","article-title":"Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement","volume":"39","author":"Antonescu","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R13-20251215","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/modpathol.2014.165","article-title":"Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors","volume":"28","author":"Hornick","year":"2015","journal-title":"Mod Pathol"},{"key":"R14-20251215","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/his.12910","article-title":"ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours","volume":"69","author":"Yamamoto","year":"2016","journal-title":"Histopathology"},{"key":"R15-20251215","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/PAS.0000000000000677","article-title":"ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory myofibroblastic tumors","volume":"40","author":"Alassiri","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R16-20251215","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41379-019-0406-6","article-title":"Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 cases","volume":"33","author":"Lopez-Nunez","year":"2020","journal-title":"Mod Pathol"},{"key":"R18-20251215","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/0046-8177(93)90217-5","article-title":"Pseudosarcomatous fibromyxoid tumor of the urinary bladder and prostate: immunohistochemical, ultrastructural, and DNA flow cytometric analyses of nine cases","volume":"24","author":"Ro","year":"1993","journal-title":"Hum Pathol"},{"key":"R19-20251215","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/01.pas.0000208903.46354.6f","article-title":"Pseudosarcomatous myofibroblastic proliferations of the bladder: a clinicopathologic study of 42 cases","volume":"30","author":"Harik","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"R20-20251215","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.5858\/arpa.2012-0326-RA","article-title":"Low-grade myofibroblastic proliferations of the urinary bladder","volume":"137","author":"Alquati","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"R21-20251215","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2559.2006.02376.x","article-title":"ALK expression in pseudosarcomatous myofibroblastic proliferations of the genitourinary tract","volume":"48","author":"Hirsch","year":"2006","journal-title":"Histopathology"},{"key":"R22-20251215","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41379-020-00670-0","article-title":"Pseudosarcomatous myofibroblastic proliferations of the urinary bladder are neoplasms characterized by recurrent FN1-ALK fusions","volume":"34","author":"Acosta","year":"2021","journal-title":"Mod Pathol"},{"key":"R23-20251215","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1097\/01.pas.0000213280.35413.1b","article-title":"Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma","volume":"30","author":"Montgomery","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"R24-20251215","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.urology.2014.05.039","article-title":"Inflammatory myofibroblastic tumors of the urinary bladder: a systematic review","volume":"84","author":"Teoh","year":"2014","journal-title":"Urology"},{"key":"R25-20251215","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.juro.2008.06.049","article-title":"Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum?","volume":"180","author":"Cheng","year":"2008","journal-title":"J Urol"},{"key":"R26-20251215","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/00000478-200412000-00009","article-title":"ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder","volume":"28","author":"Tsuzuki","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"R27-20251215","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1440-1827.2006.02012.x","article-title":"Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene","volume":"56","author":"Yamamoto","year":"2006","journal-title":"Pathol Int"},{"key":"R28-20251215","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.humpath.2017.04.022","article-title":"A novel fusion of HNRNPA1-ALK in inflammatory myofibroblastic tumor of urinary bladder","volume":"69","author":"Inamura","year":"2017","journal-title":"Hum Pathol"},{"key":"R29-20251215","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/pbc.25424","article-title":"FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor","volume":"62","author":"Ouchi","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R30-20251215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.urology.2020.09.026","article-title":"Inflammatory myofibroblastic tumor of the bladder with FN1-ALK gene fusion: different response to ALK inhibition","volume":"146","author":"Reinhart","year":"2020","journal-title":"Urology"},{"key":"R31-20251215","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/his.14206","article-title":"TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder","volume":"77","author":"Bertz","year":"2020","journal-title":"Histopathology"},{"key":"R32-20251215","doi-asserted-by":"crossref","first-page":"e30172","DOI":"10.1002\/pbc.30172","article-title":"Pediatric inflammatory myofibroblastic tumor of the bladder with ALK-FN1 fusion successfully treated by alectinib","volume":"70","author":"Fujiki","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"R33-20251215","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3892\/ol.2023.13813","article-title":"Inflammatory myofibroblastic tumor of the urinary bladder with FN1\u2011ALK gene fusion: a case report","volume":"25","author":"Son","year":"2023","journal-title":"Oncol Lett"},{"key":"R34-20251215","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.5858\/arpa.2021-0230-OA","article-title":"Assessment of ALK fusions in uncommon inflammatory myofibroblastic tumors with ALK IHC positivity but FISH-equivocal findings by targeted RNA sequencing","volume":"146","author":"Yao","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"R35-20251215","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/his.13526","article-title":"Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically different from nodular fasciitis and lack USP6, ROS1 and ETV6 gene rearrangements","volume":"73","author":"Jebastin","year":"2018","journal-title":"Histopathology"},{"key":"R36-20251215","first-page":"1024","article-title":"[Inflammatory myofibroblastic tumors of the urinary bladder: a clinicopathological study of ten cases]","volume":"50","author":"Zhang","year":"2021","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"R37-20251215","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/his.12619","article-title":"Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in-situ hybridization for the detection of anaplastic lymphoma kinase alterations","volume":"67","author":"Choi","year":"2015","journal-title":"Histopathology"},{"key":"R38-20251215","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bju.15638","article-title":"Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder","volume":"130","author":"Hensley","year":"2022","journal-title":"BJU Int"},{"key":"R39-20251215","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1242\/jcs.00059","article-title":"Fibronectin at a glance","volume":"115","author":"Pankov","year":"2002","journal-title":"J Cell Sci"},{"key":"R40-20251215","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.matbio.2005.06.008","article-title":"Fibronectin fibrillogenesis, a cell-mediated matrix assembly process","volume":"24","author":"Mao","year":"2005","journal-title":"Matrix Biol"},{"key":"R41-20251215","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/PAS.0000000000000801","article-title":"Uterine inflammatory myofibroblastic tumors frequently harbor ALK fusions with IGFBP5 and THBS1","volume":"41","author":"Haimes","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R42-20251215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10014-021-00416-z","article-title":"Epithelioid inflammatory myofibroblastic sarcoma with VCL-ALK fusion of central nervous system: case report and brief review of the literature","volume":"39","author":"Chopra","year":"2022","journal-title":"Brain Tumor Pathol"},{"key":"R43-20251215","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00381-021-05219-3","article-title":"DCTN1-ALK gene fusion in inflammatory myofibroblastic tumor (IMT) of the CNS","volume":"37","author":"Vidrine","year":"2021","journal-title":"Childs Nerv Syst"},{"key":"R44-20251215","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1158\/1078-0432.CCR-11-0063","article-title":"Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification","volume":"17","author":"Takeuchi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R45-20251215","first-page":"1595","article-title":"Targeting tropomyosin-receptor kinase fused gene in cancer","volume":"34","author":"Chen","year":"2014","journal-title":"Anticancer Res"},{"key":"R46-20251215","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-12-2851","article-title":"Molecular pathways: ROS1 fusion proteins in cancer","volume":"19","author":"Davies","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R47-20251215","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","article-title":"Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor","volume":"363","author":"Butrynski","year":"2010","journal-title":"N Engl J Med"},{"key":"R48-20251215","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/cancers11030275","article-title":"Targeting ALK in cancer: therapeutic potential of proapoptotic peptides","volume":"11","author":"Aubry","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R49-20251215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijscr.2018.04.027","article-title":"Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: a case report","volume":"48","author":"Nagumo","year":"2018","journal-title":"Int J Surg Case Rep"},{"key":"R50-20251215","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1097\/MPH.0000000000002185","article-title":"Rapid response to lorlatinib in a patient with TFG-ROS1 fusion positive inflammatory myofibroblastic tumor of the chest wall metastatic to the brain and refractory to first and second generation ROS1 inhibitors","volume":"43","author":"Carcamo","year":"2021","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:02:44Z","timestamp":1765814564000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002477"}},"subtitle":["A Study of 20 Cases With Predominant FN1::ALK Fusions and Novel Kinase Rearrangements"],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002477","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"2025-07-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}